



**Item 7.01 Regulation FD Disclosure.**

Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts at industry conferences and various other meetings between June 1, 2023 and June 30, 2023. During these conferences and meetings, the Company intends to reaffirm its guidance of at least \$27.88 in diluted earnings per common share ("EPS") or at least \$28.25 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2023 ("FY 2023"). This guidance is consistent with the guidance issued in Humana's press release dated April 26, 2023. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company's website at [www.humana.com](http://www.humana.com).

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, is useful to both management and its investors in analyzing the Company's ongoing business and operating performance. Consequently, management uses Adjusted EPS as an indicator of the Company's business performance, as well as for operational planning and decision making purposes. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

<b>Diluted earnings per common share</b>	<b>FY 2023 Guidance</b>
<b>GAAP</b>	<b><i>at least \$27.88</i></b>
Amortization of identifiable intangibles	0.50
Put/call valuation adjustments associated with Company's non-consolidating minority interest investments	0.42
Transaction and integration costs	(0.41)
Change in fair market value of publicly-traded equity securities	(0.01)
Impact of exit of employer group commercial medical products business	0.13
Tax impact of non-GAAP adjustments	(0.26)
<b>Adjusted (non-GAAP) – FY 2023 projected</b>	<b><i>at least \$28.25</i></b>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**HUMANA INC.**

**BY:** /s/ John-Paul W. Felter

**John-Paul W. Felter**

**Senior Vice President, Chief Accounting Officer &  
Controller**

**(Principal Accounting Officer)**

Dated: June 1, 2023